ProCE Banner Activity

CE / CME

Contemporary Management of HIV: Heavily Treatment–Experienced Patients

Gain expert insights on treatment strategies for heavily treatment–experienced patients with HIV. Topics include assessment of virologic failure, current treatment options for patients with multiclass drug resistance, and guidance on selecting the next line of therapy for patients experiencing virologic failure due to resistance.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: December 22, 2020

Expiration: December 21, 2021

No longer available for credit.

Share

Faculty

Roger Bedimo

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Eric S. Daar

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Joseph J. Eron, Jr.

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
Associate Director
, Clinical Research Unit
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Target Audience

This program is intended for physicians, registered nurses, physician assistants, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Perform appropriate assessments of patients with virologic failure in the setting of extensive treatment history and complex resistance, assessing factors contributing to failure and clinical and laboratory parameters relevant to the selection of a new regimen
  • Appropriately counsel patients on potential management strategies for virologic failure in the setting of an extensive treatment history and multiclass drug resistance
  • Describe the mechanisms of action, efficacy, and safety of agents with activity against multidrug-resistant HIV in treatment-experienced patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
Associate Director
, Clinical Research Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Faculty Disclosure

Primary Author

Roger Bedimo, MD, MS, FACP

Associate Professor of Medicine
Division of Infectious Diseases
University of Texas Southwestern Medical Center
Section Chief
Division of Infectious Diseases
Department of Internal Medicine
VA North Texas Health Care System
Dallas, Texas

Roger Bedimo, MD, MS, FACP, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare and funds for research support from ViiV Healthcare.

Eric S. Daar, MD

Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Eric S. Daar, MD, has disclosed that he has received consulting fees from Genentech, Gilead Sciences, and ViiV Healthcare and funds for research support from Gilead Sciences, Merck, and ViiV Healthcare.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-155-H02-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 22, 2020, through December 21, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ competence in providing optimal care for HIV-infected patients through the appropriate use of contemporary ARV regimens.